HOME > ARCHIVE
ARCHIVE
- BULLETIN
August 25, 2003
- Korosho Collects Data to Decide Reevaluation of Gastric Ulcer, Cataract Drugs
August 25, 2003
- Financial Results in 1st Quarter
August 25, 2003
- GERD Add. Indication to Boost Sales of Pariet: Eisai
August 25, 2003
- Fujisawa Endows Chair of Theoretical Drug Design
August 25, 2003
- BULLETIN
August 25, 2003
- Takeda Assesses Intellectual Property Management Based on Costs, Benefits
August 25, 2003
- DIAGNOSTIC NEWS IN BRIEF
August 11, 2003
- NEW PRODUCTS
August 11, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 11, 2003
- Warning against Facile Use of Antibiotics to Treat Colds: JRS GL
August 11, 2003
- AnGes MG Granted Patent Rights on HGF Gene Therapy
August 11, 2003
- Sosei Raises \1.6 Billion to Finance Development
August 11, 2003
- Part of Revised PAL Goes into Effect on July 30
August 11, 2003
- Financial Results in 1st Quarter
August 11, 2003
- National Medical Costs Rose 3.2% in FY2001: Korosho
August 11, 2003
- REGULATORY NEWS IN BRIEF
August 11, 2003
- Natural Increases in Social Insurance Spending to Become \687 Bil.
August 11, 2003
- METI to Prepare GL for Disclosure of Information on Patents
August 11, 2003
- Maruko Enters Itochu Group
August 11, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
